The adefovir example builds on our previous modeling efforts of OAT substrates (PDA [21], ganciclovir [45]) increasing the confidence and robustness of PBPK modeling in predicting changes to the pharmacokinetics of OAT drugs in CKD. Here, OAT is linked to chronic kidney disease.